Trending NewsTrending NewsNASDAQ:AMRX Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis $18.71 +0.43 (+2.35%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$19.03 +0.32 (+1.71%) As of 09/18/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amneal Pharmaceuticals Stock (NASDAQ:AMRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amneal Pharmaceuticals alerts:Sign Up Key Stats Today's Range$18.06▼$18.8150-Day Range$16.65▼$19.1052-Week Range$9.49▼$19.26Volume6.62 million shsAverage Volume1.73 million shsMarket Capitalization$5.98 billionP/E Ratio38.18Dividend YieldN/APrice Target$20.14Consensus RatingModerate Buy Company Overview Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture. The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories. Its portfolio includes treatments for conditions such as Parkinson’s disease, epilepsy and diabetes, as well as products for other chronic and specialty-care needs. Amneal was formed through the combination of Amneal Pharmaceuticals and Impax Laboratories, which became a publicly traded company in 2018. Based in Bridgewater, New Jersey, the company serves customers in the United States and selected international markets. Amneal is led by co-chief executive officers Chirag Patel and Chintu Patel, who are also among the company’s founders.AI Generated. May Contain Errors. Read More Amneal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreAMRX MarketRank™: Amneal Pharmaceuticals scored higher than 67% of companies evaluated by MarketBeat, and ranked 249th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingAmneal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Amneal Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAmneal Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amneal Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth14.89% Earnings GrowthEarnings for Amneal Pharmaceuticals are expected to grow by 14.89% in the coming year, from $0.94 to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amneal Pharmaceuticals is 38.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Amneal Pharmaceuticals is 38.18, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.22. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.00% of the float of Amneal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmneal Pharmaceuticals has a short interest ratio ("days to cover") of 7.41.Change versus previous monthShort interest in Amneal Pharmaceuticals has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmneal Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmneal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.49 News SentimentAmneal Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,216,567.00 in company stock.Percentage Held by Insiders17.30% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.82% of the stock of Amneal Pharmaceuticals is held by institutions.Read more about Amneal Pharmaceuticals' insider trading history. Receive AMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRX Stock News HeadlinesAmneal Pharma Gains FDA Approval For Lanreotide InjectionSeptember 19 at 1:26 AM | rttnews.comAmneal Pharmaceuticals, Inc. Announces FDA Approval And Launch Of Lanreotide InjectionSeptember 18 at 8:26 PM | marketscreener.comMThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.September 19 at 1:00 AM | Porter & Company (Ad)Amneal Gets FDA Approval for Generic Hormone DrugSeptember 18 at 8:26 PM | marketscreener.comMAmneal Pharmaceuticals Secures FDA Approval for Lanreotide InjectionSeptember 18 at 8:26 PM | finance.yahoo.comAmneal Gains FDA Approval For Generic Lanreotide Injection; Launches Drug ImmediatelySeptember 18 at 8:26 PM | rttnews.comAMRX stock advances as generic to Ipsen’s hormone shot gets FDA nodSeptember 18 at 8:26 PM | msn.comAmneal Announces FDA Approval and Launch of Lanreotide InjectionSeptember 18 at 4:01 PM | globenewswire.comSee More Headlines AMRX Stock Analysis - Frequently Asked Questions How have AMRX shares performed this year? Amneal Pharmaceuticals' stock was trading at $12.60 at the start of the year. Since then, AMRX stock has increased by 48.5% and is now trading at $18.71. How were Amneal Pharmaceuticals' earnings last quarter? Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) released its quarterly earnings results on Thursday, July, 30th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.24 by $0.06. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative trailing twelve-month return on equity of 584.46% and a net margin of 5.05%. Read the conference call transcript. Who are Amneal Pharmaceuticals' major shareholders? Top institutional shareholders of Amneal Pharmaceuticals include Assenagon Asset Management S.A. (0.77%), Bank of New York Mellon Corp (0.32%), RPg Family Wealth Advisory LLC (0.12%) and California State Teachers Retirement System (0.06%). Insiders that own company stock include Tushar Bhikhubhai Patel, Gautam Patel, Ted C Nark, Nikita Shah, John Kiely, Andrew S Boyer, Deborah M Autor and Jason B Daly. View institutional ownership trends. How do I buy shares of Amneal Pharmaceuticals? Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amneal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), TotalEnergies (TTE), Voyager Therapeutics (VYGR), Broadcom (AVGO) and Waste Connections (WCN). Company Calendar Last Earnings7/30/2026Today9/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AMRX's financial health is in the Green zone, according to TradeSmith. AMRX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMRX Previous SymbolNASDAQ:AMRX CIK1723128 Webamneal.com Phone908-947-3120Fax908-947-3146Employees8,500Year Founded2002Price Target and Rating Average Price Target for Amneal Pharmaceuticals$20.14 High Price Target$25.00 Low Price Target$13.00 Potential Upside/Downside+7.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.49 Trailing P/E Ratio38.18 Forward P/E Ratio19.90 P/E GrowthN/ANet Income$72.06 million Net Margins5.05% Pretax Margin6.45% Return on Equity-584.46% Return on Assets7.78% Debt Debt-to-Equity Ratio77.65 Current Ratio2.20 Quick Ratio1.44 Sales & Book Value Annual Sales$3.02 billion Price / Sales1.98 Cash Flow$1.60 per share Price / Cash Flow11.71 Book Value($0.23) per share Price / Book-81.35Miscellaneous Outstanding Shares319,350,000Free Float264,106,000Market Cap$5.98 billion OptionableOptionable Beta1.24 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AMRX) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
